Emerald Health Awarded 6 Patents for Potential Cannabis Treatments

Emerald Health Pharmaceuticals (EHP), the company developing the synthetic cannabis-derived EHP-101 as a treatment for scleroderma, has been granted six patents related to 25 new molecules derived from cannabidiol (CBD) and cannabigerol (CBG).

The new patents were granted in Japan, Israel, Australia, and Russia. Both CBD and CBG are isolated from the cannabis plant.

“The granting of these patents further expands the protection of our platform technology,” Jim DeMesa, MD, president and CEO of Emerald, said in a press release. “We plan to continue expanding and broadening this protection for our large portfolio of novel molecules.”

Adding these six patents brings Emerald’s total to 17, with another 21 patents still pending.

The patents cover the composition, formulation, and use of such compounds as treatments for scleroderma and other disorders, including multiple sclerosis, and Huntington’s and Parkinson’s diseases. They provide protection until 2040 and may qualify for extension.

Leave a Reply